SUPN
SUPERNUS PHARMACEUTICALS, INC.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $32 | $48 | +51% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $33 | $48 | +45% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $33 | $48 | +45% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $33 | $48 | +45% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $33 | $48 | +45% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $33 | $48 | +45% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $33 | $48 | +45% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Maverick Capital 3× in & out | Q4 2022 | Q4 2023 | → $28 | -19% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at SUPERNUS PHARMACEUTICALS, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Mar 18, 2026 — the most recent Form 4 on file — not from today.
- Form 40001539215-26-000008Mar 18, 2026
- Form 40001539937-26-000008Mar 16, 2026
- Form 40001438462-26-000006Mar 16, 2026
- Form 40001539937-26-000006Mar 10, 2026
- Form 40001804567-26-000010Mar 10, 2026
- Form 40001194020-26-000010Mar 10, 2026
- Form 40002117599-26-000004Mar 10, 2026
- Form 40001256088-26-000006Mar 9, 2026
- Form 40001539937-26-000004Mar 3, 2026
- Form 40001194020-26-000008Mar 3, 2026
- Form 40001804567-26-000008Mar 3, 2026
- Form 40001804567-26-000006Feb 26, 2026
- Form 40001194020-26-000006Feb 26, 2026
- Form 40001539215-26-000006Feb 26, 2026
- Form 40001836067-26-000006Feb 26, 2026
Fundamentals
XBRL · SUPERNUS PHARMACEUTICALS, INC.Annual figures sourced directly from SUPERNUS PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for SUPERNUS PHARMACEUTICALS, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 20, 2026
- 10-QQuarterly reportMay 5, 2026
- 8-KMaterial eventMay 5, 2026
- DEF 14AFORM DEF 14AApr 30, 2026
- 8-KMaterial eventApr 22, 2026
- 8-KFORM 8-KApr 7, 2026
- 10-KAnnual reportMar 2, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-KMaterial eventFeb 12, 2026
- 8-KMaterial eventJan 28, 2026
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 4, 2025
- 8-KMaterial eventOct 21, 2025
- 8-K/A8-KOct 16, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2025 | open | $39 | $48 | +24% |
| Citadel Advisors | Q3 2024 | open | $33 | $48 | +45% |
| Two Sigma Investments | Q3 2024 | open | $33 | $48 | +45% |
| D.E. Shaw | Q3 2024 | open | $33 | $48 | +45% |
| AQR Capital Management | Q3 2024 | open | $33 | $48 | +45% |
| Millennium Management | Q3 2024 | open | $33 | $48 | +45% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $33 | $36 | +9% |
| Renaissance Technologies | Q3 2024 | open | $32 | $48 | +51% |
| Maverick Capital | Q4 2022 | Q4 2023 | $35 | $28 | -19% |
| Maverick Capital | Q3 2021 | Q2 2022 | $25 | $27 | +11% |
| Maverick Capital | Q4 2020 | Q2 2021 | $22 | $31 | +38% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.